[go: up one dir, main page]

WO2018217064A3 - 형질전환된 t세포를 이용한 자연살해세포의 배양방법 - Google Patents

형질전환된 t세포를 이용한 자연살해세포의 배양방법 Download PDF

Info

Publication number
WO2018217064A3
WO2018217064A3 PCT/KR2018/005983 KR2018005983W WO2018217064A3 WO 2018217064 A3 WO2018217064 A3 WO 2018217064A3 KR 2018005983 W KR2018005983 W KR 2018005983W WO 2018217064 A3 WO2018217064 A3 WO 2018217064A3
Authority
WO
WIPO (PCT)
Prior art keywords
natural killer
transformed
cells
cell
culturing
Prior art date
Application number
PCT/KR2018/005983
Other languages
English (en)
French (fr)
Other versions
WO2018217064A2 (ko
Inventor
민보경
박경민
김현아
양빛나
황유경
김효진
Original Assignee
주식회사 녹십자랩셀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 녹십자랩셀 filed Critical 주식회사 녹십자랩셀
Priority to CA3062130A priority Critical patent/CA3062130A1/en
Priority to CN201880034893.8A priority patent/CN110662834B/zh
Priority to EP18805231.0A priority patent/EP3633029A4/en
Priority to AU2018271755A priority patent/AU2018271755B2/en
Priority to JP2019565241A priority patent/JP7039623B2/ja
Priority to KR1020197030133A priority patent/KR102460173B1/ko
Priority to US16/613,601 priority patent/US12203065B2/en
Publication of WO2018217064A2 publication Critical patent/WO2018217064A2/ko
Publication of WO2018217064A3 publication Critical patent/WO2018217064A3/ko
Priority to US18/977,119 priority patent/US20250109380A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)

Abstract

본 발명은 형질전환된 T세포를 이용한 자연살해세포의 배양방법에 관한 것이다. 본 발명의 형질전환된 T세포를 이용한 자연살해세포의 배양방법은 소량의 원료세포로부터 자연살해세포를 효과적으로 증식시켜 제조할 수 있다. 또한, 자연살해세포의 세포살해능도 향상시킨다. 따라서, 본 발명의 형질전환된 T세포를 이용한 자연살해세포의 배양방법은 세포치료제 상용화에 유용하게 사용될 수 있다. 나아가, 본 발명의 배양방법으로 제조된 자연살해세포는 세포치료제로서 유용하게 사용될 수 있다.
PCT/KR2018/005983 2017-05-26 2018-05-25 형질전환된 t세포를 이용한 자연살해세포의 배양방법 WO2018217064A2 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA3062130A CA3062130A1 (en) 2017-05-26 2018-05-25 Method for culturing natural killer cell, using transformed t cell
CN201880034893.8A CN110662834B (zh) 2017-05-26 2018-05-25 使用转化的t细胞培养自然杀伤细胞的方法
EP18805231.0A EP3633029A4 (en) 2017-05-26 2018-05-25 METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
AU2018271755A AU2018271755B2 (en) 2017-05-26 2018-05-25 Method for culturing natural killer cell, using transformed T cell
JP2019565241A JP7039623B2 (ja) 2017-05-26 2018-05-25 形質転換されたｔ細胞を用いてナチュラルキラー細胞を培養する方法
KR1020197030133A KR102460173B1 (ko) 2017-05-26 2018-05-25 형질전환된 t세포를 이용한 자연살해세포의 배양방법
US16/613,601 US12203065B2 (en) 2017-05-26 2018-05-25 Method for culturing natural killer cell, using transformed T cell
US18/977,119 US20250109380A1 (en) 2017-05-26 2024-12-11 Method for culturing natural killer cell, using transformed t cell

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0065180 2017-05-26
KR20170065180 2017-05-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/613,601 A-371-Of-International US12203065B2 (en) 2017-05-26 2018-05-25 Method for culturing natural killer cell, using transformed T cell
US18/977,119 Division US20250109380A1 (en) 2017-05-26 2024-12-11 Method for culturing natural killer cell, using transformed t cell

Publications (2)

Publication Number Publication Date
WO2018217064A2 WO2018217064A2 (ko) 2018-11-29
WO2018217064A3 true WO2018217064A3 (ko) 2019-03-28

Family

ID=64396946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005983 WO2018217064A2 (ko) 2017-05-26 2018-05-25 형질전환된 t세포를 이용한 자연살해세포의 배양방법

Country Status (8)

Country Link
US (2) US12203065B2 (ko)
EP (1) EP3633029A4 (ko)
JP (1) JP7039623B2 (ko)
KR (1) KR102460173B1 (ko)
CN (1) CN110662834B (ko)
AU (1) AU2018271755B2 (ko)
CA (1) CA3062130A1 (ko)
WO (1) WO2018217064A2 (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
KR102460173B1 (ko) 2017-05-26 2022-10-31 주식회사 지씨셀 형질전환된 t세포를 이용한 자연살해세포의 배양방법
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US12116417B2 (en) 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
PH12021550950A1 (en) * 2018-11-14 2022-05-02 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t cells
CN111304255B (zh) * 2020-02-21 2023-06-09 中邦干细胞科技有限公司 一种滋养细胞、其制备方法及其在高效扩增nk细胞中的应用
US20230203442A1 (en) * 2020-06-09 2023-06-29 Samsung Life Public Welfare Foundation Genetically-modified cell line for nk cell activation and amplification, and use thereof
CN112048482A (zh) * 2020-09-09 2020-12-08 广东昭泰体内生物医药科技有限公司 一种nk样细胞的培养方法
CA3205631A1 (en) * 2020-12-17 2022-06-23 Artiva Biotherapeutics, Inc. Expanded and stimulated natural killer cells
JP2024520103A (ja) * 2021-06-01 2024-05-21 ヴァクセル－バイオ フィーダー細胞を含むナチュラルキラー細胞増殖用組成物
CN113599395B (zh) * 2021-09-22 2022-08-12 郑州源创吉因实业有限公司 含有nk细胞的治疗癌症的药物组合物
WO2023080895A1 (en) * 2021-11-04 2023-05-11 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers
JP7585560B2 (ja) * 2022-10-07 2024-11-18 東京エレクトロン株式会社 基板処理システム及びエッジリングの取り付け方法
WO2024153124A1 (zh) * 2023-01-18 2024-07-25 南京传奇生物科技有限公司 经修饰的原代t细胞及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102911918A (zh) * 2011-12-29 2013-02-06 上海交通大学医学院 一种基因工程细胞及其在nk细胞扩增中的应用
JP5840837B2 (ja) * 2007-03-30 2016-01-06 メモリアル スローン−ケタリング キャンサー センター 養子移入ｔリンパ球における副刺激リガンドの構成性発現
CN106222141A (zh) * 2016-10-17 2016-12-14 湖南丰晖生物科技有限公司 Nk细胞培养液和细胞培养方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5840837U (ja) 1981-09-12 1983-03-17 三菱電機株式会社 ウエ−ハ洗浄乾燥装置
US5766601A (en) 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
EP0852618A1 (en) 1995-07-25 1998-07-15 Celltherapy Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
CA2247131A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
WO1998006822A1 (en) 1996-08-08 1998-02-19 Yoshitomi Pharmaceutical Industries, Ltd. Culture medium and use of the same
JP2004501110A (ja) 2000-05-23 2004-01-15 ネクセル　セラピューティックス　インコーポレイティド 細胞選択用試薬および使用方法
US20030068306A1 (en) 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
WO2005007116A2 (en) 2003-07-18 2005-01-27 Valeocyte Therapies Llc Artificial antigen presenting cell devices
GB0318913D0 (en) * 2003-08-12 2003-09-17 Ist Superiore Sanita Apoptosis inhibitors
PL1739166T3 (pl) 2005-07-01 2012-01-31 Txcell S A Otrzymywanie komórek Tr1 specyficznych wobec antygenu pokarmowego lub autoantygenu z populacji leukocytów lub PBMC
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
US7628528B2 (en) 2005-10-26 2009-12-08 PRS Biotech, Inc. Pneumatic bioreactor
US20080261299A1 (en) 2007-04-23 2008-10-23 Zeikus J Gregory Pneumatic Bioreactor
KR20080008060A (ko) 2006-07-19 2008-01-23 전남대학교산학협력단 자연살해세포의 제조 방법
EP2052075A4 (en) 2006-08-23 2010-05-26 Binex Co Ltd METHOD OF PREPARING ACTIVATED LYMPHOCYTES FOR IMMUNOTHERAPY
US20080138833A1 (en) 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
CN101302491B (zh) 2007-05-09 2011-09-14 王歈 高效扩增活化淋巴细胞的方法和培养系统
KR101299299B1 (ko) 2007-11-05 2013-08-26 츠네오 쿠라모치 암면역 요법용 세포의 제조방법
WO2009132283A2 (en) * 2008-04-24 2009-10-29 University Of Miami Method for treating autoimmune disorders
US20090269849A1 (en) 2008-04-25 2009-10-29 Pbs Biotech, Inc. Bioreactor Apparatus
KR101035556B1 (ko) 2008-05-22 2011-05-23 재단법인 목암생명공학연구소 자연살해세포의 제조방법, 이러한 방법에 의해 제조된자연살해세포, 및 이를 유효성분으로 포함하는 고형 종양치료용 조성물
KR20090127974A (ko) 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물
KR101043588B1 (ko) 2008-07-25 2011-06-22 재단법인 철원플라즈마 산업기술연구원 내 플라즈마 세라믹 코팅막 형성방법
KR101133185B1 (ko) 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
CN102428173B (zh) 2009-03-26 2014-07-30 细胞维护北欧制药公司 Nk细胞的扩增
WO2011030851A1 (ja) 2009-09-11 2011-03-17 タカラバイオ株式会社 ナチュラルキラー細胞の製造方法
WO2011080740A1 (en) 2009-12-29 2011-07-07 Gamida-Cell Ltd. Methods for enhancing natural killer cell proliferation and activity
NO2606125T3 (ko) 2010-08-20 2018-04-21
KR101298012B1 (ko) 2011-02-08 2013-08-26 (주)차바이오앤디오스텍 암세포로의 표적지향을 위한 자연살해 세포를 포함하는 림프구의 제조방법 및 이를 포함하는 약학 조성물
CA2830080C (en) 2011-03-18 2021-10-26 Jan Spanholtz Generation of nk cells and nk-cell progenitors
EP2702145A1 (en) 2011-04-28 2014-03-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for preparing accessory cells and uses thereof for preparing activated nk cells
JP5840876B2 (ja) 2011-06-24 2016-01-06 テラ株式会社 Ｎｋ細胞を増幅するための組成物及び方法
JP5572863B2 (ja) 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
JP5847518B2 (ja) 2011-09-28 2016-01-20 株式会社日本バイオセラピー研究所 Ｎｋ細胞強化型血液製剤の製造方法
NO2794859T3 (ko) 2011-12-22 2018-02-17
JP6422344B2 (ja) 2012-03-02 2018-11-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 同種抗原反応性の制御性ｔ細胞を増大させる方法
CN104321425B (zh) 2012-05-07 2018-08-10 株式会社Nkmax 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
JP5511039B1 (ja) 2013-05-22 2014-06-04 国立大学法人九州大学 Ｎｋ細胞の調製方法
MY186846A (en) * 2014-04-10 2021-08-26 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
WO2016029043A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
JP7049830B2 (ja) * 2014-10-27 2022-04-07 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド ナチュラルキラー細胞のための方法及び組成物
AU2015339106B2 (en) * 2014-10-31 2020-07-02 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding T cells
CN105602899B (zh) 2014-11-25 2019-03-08 天津天锐生物科技有限公司 一种白细胞介素21和4-1bbl诱导外周血单个核细胞中nk细胞增殖的方法
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
KR101706524B1 (ko) 2014-12-03 2017-02-14 주식회사 녹십자랩셀 안정성 높은 자연살해세포의 효율적인 제조방법
GB201503500D0 (en) * 2015-03-02 2015-04-15 Ucl Business Plc Cell
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
AU2016256911B2 (en) 2015-05-07 2022-03-31 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
US20190037831A1 (en) 2016-02-01 2019-02-07 Green Cross Lab Cell Corporation Medium composition for cryopreservation of cell and use thereof
US20190336533A1 (en) 2016-12-28 2019-11-07 Green Cross Lab Cell Corporation Chimeric antigen receptor and natural killer cells expressing same
CN108300697A (zh) 2017-01-13 2018-07-20 上海恒润达生生物科技有限公司 一种滋养细胞刺激nk细胞扩增的方法和用途
GB201706451D0 (en) 2017-04-24 2017-06-07 Imp Innovations Ltd Cancer treatment
KR102460173B1 (ko) 2017-05-26 2022-10-31 주식회사 지씨셀 형질전환된 t세포를 이용한 자연살해세포의 배양방법
US12116417B2 (en) 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN108300693A (zh) 2018-01-25 2018-07-20 河北省健海生物芯片技术有限责任公司 一种自然杀伤细胞体外扩增方法
KR102232321B1 (ko) 2018-03-23 2021-03-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
WO2019182392A1 (ko) 2018-03-23 2019-09-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020101361A1 (ko) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법
KR20230024911A (ko) 2020-05-22 2023-02-21 주식회사 지씨셀 항-her2 항체 또는 이의 항원 결합 단편 및 이를 포함하는 키메라 항원 수용체
WO2022133061A1 (en) 2020-12-17 2022-06-23 Artiva Biotherapeutics, Inc. Infusion ready cryopreservation compositions
CA3205631A1 (en) 2020-12-17 2022-06-23 Artiva Biotherapeutics, Inc. Expanded and stimulated natural killer cells
US20240000840A1 (en) 2020-12-17 2024-01-04 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd20 targeted antibody
KR20240024047A (ko) 2021-04-08 2024-02-23 아티바 바이오테라퓨틱스, 인크. Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법
KR20230167416A (ko) 2021-04-08 2023-12-08 주식회사 지씨셀 키메라 항원 수용체 및 il-15를 포함하는 융합 단백질
AU2022253889A1 (en) 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and an egfr targeted antibody
JP2024513522A (ja) 2021-04-08 2024-03-25 アルティヴァ バイオセラピューティクス インコーポレイテッド Ｎｋ細胞およびｈｅｒ２標的抗体を用いた癌治療
WO2022216813A1 (en) 2021-04-08 2022-10-13 Artiva Biotherapeutics, Inc. Chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the same
WO2022216811A2 (en) 2021-04-08 2022-10-13 Artiva Biotherapeutics, Inc. Chimeric antigen receptor comprising an anti-cd19 antibody or antigen-binding fragment thereof and natural killer cells comprising the same
EP4319769A4 (en) 2021-04-08 2025-01-01 Artiva Biotherapeutics Inc CANCER TREATMENT WITH NK CELLS AND AN ANTIBODY TARGETING CD20
WO2023080895A1 (en) 2021-11-04 2023-05-11 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers
US20240424099A1 (en) 2021-11-04 2024-12-26 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and multispecific engagers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5840837B2 (ja) * 2007-03-30 2016-01-06 メモリアル スローン−ケタリング キャンサー センター 養子移入ｔリンパ球における副刺激リガンドの構成性発現
CN102911918A (zh) * 2011-12-29 2013-02-06 上海交通大学医学院 一种基因工程细胞及其在nk细胞扩增中的应用
CN106222141A (zh) * 2016-10-17 2016-12-14 湖南丰晖生物科技有限公司 Nk细胞培养液和细胞培养方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI 7 October 2008 (2008-10-07), "OX 40 ligand/ gp 34 [Homo sapiens]", XP055585825, Database accession no. CAA56284.1 *
DATABASE NCBI 8 June 2016 (2016-06-08), "TPA_inf: Homo sapiens mRNA for tumor necrosis factor ligand 5A (TNLG5A gene)", XP055585818, Database accession no. LN874322.1 *
LEE, JAE KWON ET AL.: "Development of NK Cell Expansion Methods Using Feeder Cells from Human Myelogenous Leukemia Cell Line", BLOOD RESEARCH, vol. 49, no. 3, 2014, pages 154 - 161, XP055585832 *

Also Published As

Publication number Publication date
KR102460173B1 (ko) 2022-10-31
WO2018217064A2 (ko) 2018-11-29
CN110662834A (zh) 2020-01-07
AU2018271755A1 (en) 2019-11-21
US20200108096A1 (en) 2020-04-09
KR20200001595A (ko) 2020-01-06
EP3633029A4 (en) 2021-06-09
JP2020521462A (ja) 2020-07-27
AU2018271755B2 (en) 2021-12-23
US20250109380A1 (en) 2025-04-03
CA3062130A1 (en) 2019-11-22
CN110662834B (zh) 2023-09-12
JP7039623B2 (ja) 2022-03-22
US12203065B2 (en) 2025-01-21
EP3633029A2 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
AU2018271755A1 (en) Method for culturing natural killer cell, using transformed T cell
MX2022003497A (es) Procesos para producir productos de fermentacion.
MX2020000369A (es) Metodos biologicos para preparar terpenos.
NZ737759A (en) Method of culturing akkermansia
MY169317A (en) Methods for converting lignocellulosic material to useful products
NZ703137A (en) Cells for producing recombinant iduronate-2-sulfatase
EA201390790A1 (ru) Переработка биомассы
IN2014CN03467A (ko)
EA201491418A1 (ru) Рекомбинантные микроорганизмы и способы их применения
MX2019009135A (es) Ingenieria metabolica para la produccion microbiana de productos terpenoides.
MY172080A (en) Microorganisms having putrescine productivity and process for producing putrescine using the same
PH12015500135A1 (en) Processes and systems for the production of fermentation products
EP3030647A4 (en) Methods of producing algal cell cultures and biomass, lipid compounds and compositions, and related products
MY182924A (en) Enzyme compositions and uses thereof
MX2015007361A (es) Produccion mediada por la proteina portadora de acilo de los derivados de acidos grasos.
MY193225A (en) Methods for continuous production of products from microorganisms
MX2015004173A (es) Metodos para hacer productos compuestos conteniendo lignocelulosa.
IL246525B (en) Pomegranate cell culture and methods for its preparation and use
PH12019500096A1 (en) Leuconostoc mesenteroides cjlm119 strain producing reduced amount of gas, and kimchi production method using same
NZ731398A (en) Noscapinoid-producing microbes and methods of making and using the same
MX2018013499A (es) Modulacion del metabolismo lipidico para la produccion de proteinas.
MX2017012554A (es) Microalgas adaptadas para condiciones de cultivo heterotrofo.
MX2016007054A (es) Produccion microbiana de aminas grasas.
PH12014501610A1 (en) Production of coal combustion products for use in cementitious materials
MY188407A (en) Novel lactobacillus sp. microorganisms, and composition for animal feed comprising same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18805231

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 20197030133

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3062130

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2018271755

Country of ref document: AU

Date of ref document: 20180525

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019565241

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018805231

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018805231

Country of ref document: EP

Effective date: 20200102